TY - JOUR
T1 - Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma
AU - Robetorye, Ryan S.
AU - Ramsower, Colleen A.
AU - Rosenthal, Allison C.
AU - Yip, Tameson K.
AU - Wendel Spiczka, Amy J.
AU - Glinsmann-Gibson, Betty J.
AU - Rimsza, Lisa M.
N1 - Funding Information:
Authors’ contributions R.S.R. and L.M.R.: conception, design, data analysis and interpretation, and manuscript editing C.A.R.: assay design and performance, statistical calculations, and manuscript editing A.C.R.: case identification and submission and manuscript editing T.K.Y.: assay performance and manuscript editing A.J.W.S., B.J.G-G.: assay design and performance and manuscript editing Funding information L.M.R. received funding from the Molecular Diagnosis and Prognosis in Aggressive Lymphomas, National Cancer Institute Grant #U01CA57581.
Funding Information:
Lymphoma and Leukemia Molecular Profiling Project for the science behind the Lymph2Cx assay. Center for Individualized Medicine, Mayo Clinic for support of the Molecular Diagnostics Arizona Laboratory. Lymphoma Oncologists and Hematopathologists of the Mayo Clinic in Rochester, MN, Jacksonville, FL, and Phoenix, AZ for contribution of clinical cases.
PY - 2019/3/11
Y1 - 2019/3/11
N2 - Diffuse large B cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including germinal center B cell type, activated B cell type, and unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression-profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed prospectively by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified clinical molecular diagnostics laboratory.
AB - Diffuse large B cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including germinal center B cell type, activated B cell type, and unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression-profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed prospectively by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified clinical molecular diagnostics laboratory.
KW - Cell-of-origin
KW - Diffuse large B cell lymphoma
KW - Gene expression profiling
KW - Lymph2Cx
UR - http://www.scopus.com/inward/record.url?scp=85064173588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064173588&partnerID=8YFLogxK
U2 - 10.1007/s12308-019-00344-0
DO - 10.1007/s12308-019-00344-0
M3 - Article
AN - SCOPUS:85064173588
VL - 12
SP - 3
EP - 10
JO - Journal of Hematopathology
JF - Journal of Hematopathology
SN - 1865-5785
IS - 1
ER -